Protocols
1 protocol(s) meet the specified criteria
Drug: Durvalumab
Protocol No.TitleStatus
D6410C00001A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally as a Single Agent in Subjects with Solid Tumors or CTCL and in Combination with Durvalumab and Palliative Radiation in Subjects with Solid TumorsOpen